Advanced Physician Search: KRAS

The primary purpose of this study is to evaluate the safety, pharmacokinetics, and anti-tumor activity of TLN-372 as a single agent and in combination with other anti-tumor agents, in patients with advanced KRAS mutant solid tumors

Drug: TLN-372 in combination with cetuximab, Drug: TLN-372 in combination with pembrolizumab

The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.

Drug: docetaxel